Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Oral Antidiabetic Drugs Market?

The market for oral antidiabetic drugs has experienced remarkable expansion in the previous years. The market is projected to escalate from $62.25 billion in 2024 to $66.73 billion in 2025, maintaining a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this growth during the historic period include the growing incidence of diabetes, heightened consciousness about diabetes control, an increase in the elderly population, enhanced access to modern oral antidiabetic drugs, and the advancement of healthcare infrastructure.

The oral antidiabetic drugs market is set to witness substantial expansion in the coming years, with prospects to reach $86.92 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth in the forecasted period is attributed to the escalating inclination towards novel oral antidiabetic treatments, higher investment in diabetes research, surging demand for affordable diabetes remedies, increasing incidences of type 2 diabetes globally, and a growing focus on personalized treatment for diabetes. Key trends expected during the forecast period consist of advancements in drug delivery techniques, innovations in combined therapies, integration of technology-based healthcare tools for diabetes management, manufacture of safer and more effective oral antidiabetic medications, and progression in personalized treatment strategies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25854&type=smp

Which Factor Is Shaping The Future Of The Oral Antidiabetic Drugs Market?

The escalating prevalence of type 2 diabetes is projected to drive the expansion of the oral antidiabetic drugs market. Type 2 diabetes is identified as a chronic ailment where the body is either fighting off insulin or not generating enough to manage standard glucose levels. The surge in type 2 diabetes can be attributed to rising obesity rates, with surplus body fat leading to insulin resistance and disrupted glucose regulation. Oral antidiabetic medications play a crucial role in treating type 2 diabetes by increasing insulin receptivity, augmenting insulin discharge, or curbing glucose production and absorption, ensuring proper blood sugar levels. For example, the Office for Health Improvement and Disparities, a governmental organization based in the UK, disclosed in March 2025 that the prevalence of type 2 diabetes in adults over 17 in England increased to 7.0%, up from 6.8% in March 2023. Therefore, the growing frequency of type 2 diabetes is fueling the progress of the oral antidiabetic drugs market.

What Is The Segment-Wise Breakdown Of The Oral Antidiabetic Drugs Market?

The oral antidiabetic drugs market covered in this report is segmented –

1) By Drug Class: Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Sodium Glucose Transport Protein -2 Inhibitors, Sulfonylureas, Thiazolidinediones, Megalitinides, Alpha Glucosidase Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Sublingual, Buccal

3) By Therapeutic Area: Type 2 Diabetes, Gestational Diabetes, Type 1 Diabetes

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Channels

5) By End User: Hospitals, Pharmact Store, Drug Store, Diabetes Treatment Centers, Other End Users

Subsegments:

1) By Biguanides: Metformin Hydrochloride, Metformin Extended Release, Combination Products

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

3) By Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin

4) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide

5) By Thiazolidinediones: Pioglitazone, Rosiglitazone

6) By Meglitinides: Repaglinide, Nateglinide

7) By Alpha Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose

8) By Other Drug Classes: Bromocriptine, Colesevelam

What Notable Trends Are Shaping The Direction Of The Oral Antidiabetic Drugs Market?

The key corporations functioning in the market for oral antidiabetic medications are concentrating their efforts on clinical studies in order to create safer and more efficient treatment alternatives, broaden their array of products, and secure approvals for future-generation treatments. Clinical trials, which are regulated research investigations involving human subjects, are meant to ascertain the safety, efficacy, and potential side effects of new medical treatments, drugs, or strategies. For example, in April 2025, Eli Lilly and Company, a pharmaceutical firm based in the US, launched Orforglipron, a once-daily oral GLP-1 receptor agonist molecule created to streamline diabetes management following a successful phase 3 trial. This oral treatment seeks to provide equivalent effectiveness and safety to injectable solutions while boosting patient compliance. In clinical trials, Orforglipron reduced HbA1c, an indicator of blood glucose control, by an average of 1.3% to 1.6% across various doses over a period of 40 weeks.

Which Companies Hold The Largest Market Share In The Oral Antidiabetic Drugs Sector?

Major companies operating in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oral-antidiabetic-drugs-global-market-report

How Does Regional Performance Compare Across The Oral Antidiabetic Drugs Industry?

North America was the largest region in the oral antidiabetic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral antidiabetic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25854&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model